Citigroup estimates that sales of migraine treatment Fremanezumab, which might be launched next year, could reach $2 billion annually.
Dr. Yaron Daniely reveals that Yissum gave Hebrew University over NIS 800 million in research funds, royalties, and shares over the past decade.
Joseph Weiss tells "Globes" about the challenges he faces including missile defense, exploding rocket launchers and the refusal of the US to grant him a visa.
Aerospace & defense
The Israeli data transmission and security company has seen its share price quadruple within weeks on the Australian Stock Exchange.
Some Israeli startups prefer to set up their headquarters in New York rather than Silicon Valley. Microsoft Accelerator Israel head Navot Volk explains why.
Will 2017's NIS 10 billion budget surplus - the fifth consecutive such annual surplus - be used for cutting government debt or buying voters with tax cuts?
Teva's reliance on Copaxone made the company complacent, obese, and excessively self-confident.
Shlomit Weiss reflects on 28 years of achievement at Intel and the challenges facing her as senior VP silicon engineering at Mellanox.
Nir Shalom, who runs AT&T's Israel development center, explains what it offers the US telecoms giant.
Telecoms, Media & Marketing
A heartening tale of how journalistic solidarity trumped a political illusion.
Qualcomm Israel's Assaf Touboul and Ronen Sheashua tell "Globes" about the unheard-of download speeds and greener networks coming soon.
The Israel Innovation Authority's annual report includes an operational plan for doubling the proportion of high-tech employees in the workforce over the next decade.
More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.
The FBI recently managed to arrest the CEO of an Israeli based binary options company.